Abnormal maternal serum alpha fetoprotein and pregnancy outcome

Zarzour, Steven J.; Gabert, Harvey A.; Diket, Albert L.; Amant, Marshall St.; Miller, Joseph M.

doi:10.1002/(sici)1520-6661(199811/12)7:6<304::aid-mfm9>3.0.co;2-4

Cited by 9 publications

(4 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Excluding articles that provided only studies evaluating human placental lactogen, placental alkaline phosphatase, or specific β1‐glycoprotein the findings of which were not generalizable owing to the low number of studies (File ), the literature search identified 29 articles eligible for inclusion in the meta‐regression analysis (Table and Fig. ).…”

Section: Resultsmentioning

confidence: 99%

Meta‐regression analysis to evaluate relationships between maternal blood levels of placentation biomarkers and low delivery weight

Goto

2018

Intl J Gynecology & Obste

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Meta‐regression analysis to evaluate relationships between maternal blood levels of placentation biomarkers and low delivery weight

Goto

2018

Intl J Gynecology & Obste

View full text Add to dashboard Cite

show abstract

“…There were 86 included studies for SGA [ 7 , 9 , 37 , 39 , 47 , 51 , 53 - 55 , 57 , 59 - 61 , 64 - 67 , 69 , 74 , 76 - 141 ], reporting on 382,005 women (20339 cases of SGA, incidence 5.32%). Among these studies, there were 61 cohort studies and 25 case control studies [ 53 , 55 , 76 , 77 , 82 - 85 , 88 , 89 , 94 , 96 , 97 , 104 , 113 , 116 , 119 , 123 - 125 , 130 , 131 , 133 , 135 , 140 ].…”

Section: Resultsmentioning

confidence: 99%

Serum screening with Down's syndrome markers to predict pre-eclampsia and small for gestational age: Systematic review and meta-analysis

Morris

Cnossen²,

Langejans³

et al. 2008

BMC Pregnancy Childbirth

106

View full text Add to dashboard Cite

BackgroundReliable antenatal identification of pre-eclampsia and small for gestational age is crucial to judicious allocation of monitoring resources and use of preventative treatment with the prospect of improving maternal/perinatal outcome. The purpose of this systematic review was to determine the accuracy of five serum analytes used in Down's serum screening for prediction of pre-eclampsia and/or small for gestational age.MethodsThe data sources included Medline, Embase, Cochrane library, Medion (inception to February 2007), hand searching of relevant journals, reference list checking of included articles, contact with experts. Two reviewers independently selected the articles in which the accuracy of an analyte used in Downs's serum screening before the 25th gestational week was associated with the occurrence of pre-eclampsia and/or small for gestational age without language restrictions. Two authors independently extracted data on study characteristics, quality and results.ResultsFive serum screening markers were evaluated. 44 studies, testing 169,637 pregnant women (4376 pre-eclampsia cases) and 86 studies, testing 382,005 women (20,339 fetal growth restriction cases) met the selection criteria. The results showed low predictive accuracy overall. For pre-eclampsia the best predictor was inhibin A>2.79MoM positive likelihood ratio 19.52 (8.33,45.79) and negative likelihood ratio 0.30 (0.13,0.68) (single study). For small for gestational age it was AFP>2.0MoM to predict birth weight < 10th centile with birth < 37 weeks positive likelihood ratio 27.96 (8.02,97.48) and negative likelihood ratio 0.78 (0.55,1.11) (single study). A potential clinical application using aspirin as a treatment is given as an example.There were methodological and reporting limitations in the included studies thus studies were heterogeneous giving pooled results with wide confidence intervals.ConclusionDown's serum screening analytes have low predictive accuracy for pre-eclampsia and small for gestational age. They may be a useful means of risk assessment or of use in prediction when combined with other tests.

show abstract

“…d. Multiple gestation 8 ; e. Abnormal maternal serum analytes, including α-fetoprotein level and unconjugated estriol 9 ; f. Teratogen exposure 10 ; g. First-trimester nuchal translucency measurement of 3.0 mm or greater 11 ; 4. Fetus at increased risk for a genetic or chromosomal abnormality, such as the following: a. Parental carrier of a chromosomal or genetic abnormality 3…”

Section: Indicationsmentioning

confidence: 99%

Consensus Report on the Detailed Fetal Anatomic Ultrasound Examination

Wax¹,

Minkoff

Johnson³

et al. 2014

Journal of Diagnostic Medical Sonography

View full text Add to dashboard Cite

Initially developed for detailed ultrasound studies performed for pregnancies with increased risk of fetal anomalies, there has been little consistency in the application of the Current Procedural Terminology (CPT) code 76811 ("ultrasound, pregnant uterus, real time with image documentation, maternal evaluation plus detailed fetal anatomic examination, transabdominal, single or first gestation") since it was first included in the 2003 edition of CPT. 1,2 On April 9, 2013, the AIUM and the SMFM hosted a meeting in New York, New York, to develop the appropriate indications for performing a detailed fetal anatomic ultrasound examination, the components of the examination, and the training required to interpret it. Participants included representatives from the AIUM, SMFM, ACOG, ACOOG, ACR, SDMS, and SRU.

show abstract

Abnormal maternal serum alpha fetoprotein and pregnancy outcome

Cited by 9 publications

References 12 publications

Meta‐regression analysis to evaluate relationships between maternal blood levels of placentation biomarkers and low delivery weight

Meta‐regression analysis to evaluate relationships between maternal blood levels of placentation biomarkers and low delivery weight

Serum screening with Down's syndrome markers to predict pre-eclampsia and small for gestational age: Systematic review and meta-analysis

Consensus Report on the Detailed Fetal Anatomic Ultrasound Examination

Contact Info

Product

Resources

About